SEC Form 4 · accession 0000930413-19-000024
ENZO BIOCHEM INC · ENZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Michael O'Brien
Officer — EVP of Finance
Period of report
Jan 3, 2019
Accepted (ET)
Jan 4, 2019 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000316253
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (to acquire common stock)F2,F1 | $2.80 | Jan 3, 2019 | A | 52,000 | A | Jan 4, 2020 | Jan 2, 2024 | Common Stock | 52,000 | 33,666 | D |
Explanation of responses
- F1The Reporting Person was granted 52,000 stock options. The options have a five-year term and shall vest in three equal annual tranches, beginning January 4, 2020.
- F2Does not include 10,500 Restricted Stock Units granted to the Reporting Person on January 3, 2019, which will vest, if at all, based upon (i) achievement of average revenue growth and adjusted EBITDA growth goals on January 3, 2022, and (ii) the continued service of the Reporting Person through January 3, 2022.